AstraZeneca Diabetes Drug Data Shows Significant Cut In Death Rates
Cris De Lacerda
21 Marcha, 2017, 05:56
The study assessed data from more than 300,000 patients across six countries, 87% of whom did not have a history of cardiovascular disease.
AstraZeneca announced in a statement yesterday that the world's first global "real world" trial of its kind had showed that treatment with SGLT-2i medicines, which include the group's dapagliflozin, reduced all-cause mortality by 51 percent and risk of hospitalisation for heart failure by 39 percent in patients with with type-2 diabetes.
The analysis for hospitalization for heart failure was conducted on patient data from Denmark, Germany, Norway, Sweden, U.K. and the U.S., while the analysis for death from heart failure was conducted on patient data from Denmark, Norway, Sweden, U.K. and the U.S. Around 42% of the patients were on AstraZeneca's Farxiga, around 53% on JNJ's Invokana, and rest on Jardiance.
Since 2015's report of Jardiance reducing heart-related deaths and hospitalization, it was considered as one of the best to treat cardiac complications.
The results from that trial, known as EMPA-REG, led the Food and Drug Administration a year ago to update Jardiance's label with an expanded indication for reducing the risk of cardiovascular death in adult patients with type 2 diabetes and cardiovascular disease.
The Empa-Reg Outcome reflected that Jardiance reduced cardiovascular deaths by 38 percent.
AstraZeneca has its own large cardiovascular outcomes trial, dubbed DECLARE, now under way, aimed at showing a similar benefit to Farxiga. The comparator medicines included a wide variety of diabetes treatments, including metformin, DPP-4 inhibitors, such as Merck & Co's Januvia, and insulin, among others. The study revealed that most patients used Farxiga or Invokana and less than 10 percent took Jardiance.
"This class has a real potential of improving patient outcomes", Kosiborod said. "That's not just my own hope". The heart benefit has since been incorporated into Jardiance's label. "I think this is the start of us looking at diabetes a little bit differently", said Dr. Steve Zelenkofske, head of USA medical affairs in the AstraZeneca's Cardiovascular and Metabolic Disease division.